Serotherapy in scorpion envenomation: a randomised controlled trial

Area of Science:

• Toxicology
• Emergency Medicine
• Clinical Pharmacology

Background:

• Scorpion envenomation treatment lacks robust evidence for antivenom efficacy.
• Scorpion antivenom is the primary specific treatment, yet its routine use is questioned.
• A prospective, randomized controlled trial was conducted to evaluate its effectiveness.

Purpose of the Study:

• To assess the efficacy of routine scorpion antivenom administration in scorpion-stung patients.
• To determine if antivenom prevents disease progression or aids recovery, irrespective of clinical severity.
• To provide evidence-based guidance on scorpion antivenom use.

Main Methods:

• 825 patients over 10 years old with scorpion stings were enrolled in a randomized controlled trial.
• Patients were assigned to receive either placebo or bivalent intravenous scorpion antivenom.
• Severity was graded (Grade I: no systemic manifestations; Grade II: systemic manifestations), and outcomes were assessed over 4 hours.

Main Results:

• Cure rates were similar between the scorpion antivenom group (55%) and the placebo group (66%), with no statistically significant difference.
• Preventive effects, measured by remaining symptom-free in initially Grade I patients, were also comparable between groups (94% vs. 96%).
• Time to antivenom administration did not influence curative or preventive effects.

Conclusions:

• Routine administration of scorpion antivenom showed no significant benefit in treating scorpion stings across different severity grades.
• Current evidence does not support the widespread use of scorpion antivenom when clinical severity is not a factor.
• Further research should concentrate on evaluating antivenom in patients presenting with the most severe envenomation symptoms.